全文获取类型
收费全文 | 3435篇 |
免费 | 275篇 |
国内免费 | 40篇 |
专业分类
耳鼻咽喉 | 35篇 |
儿科学 | 88篇 |
妇产科学 | 87篇 |
基础医学 | 469篇 |
口腔科学 | 16篇 |
临床医学 | 335篇 |
内科学 | 864篇 |
皮肤病学 | 47篇 |
神经病学 | 291篇 |
特种医学 | 152篇 |
外科学 | 660篇 |
综合类 | 27篇 |
一般理论 | 4篇 |
预防医学 | 161篇 |
眼科学 | 73篇 |
药学 | 197篇 |
中国医学 | 6篇 |
肿瘤学 | 238篇 |
出版年
2023年 | 9篇 |
2022年 | 31篇 |
2021年 | 68篇 |
2020年 | 79篇 |
2019年 | 107篇 |
2018年 | 113篇 |
2017年 | 56篇 |
2016年 | 86篇 |
2015年 | 108篇 |
2014年 | 161篇 |
2013年 | 181篇 |
2012年 | 275篇 |
2011年 | 256篇 |
2010年 | 157篇 |
2009年 | 133篇 |
2008年 | 211篇 |
2007年 | 204篇 |
2006年 | 230篇 |
2005年 | 197篇 |
2004年 | 169篇 |
2003年 | 153篇 |
2002年 | 138篇 |
2001年 | 26篇 |
2000年 | 28篇 |
1999年 | 30篇 |
1998年 | 54篇 |
1997年 | 38篇 |
1996年 | 35篇 |
1995年 | 33篇 |
1994年 | 22篇 |
1993年 | 22篇 |
1992年 | 24篇 |
1991年 | 25篇 |
1990年 | 26篇 |
1989年 | 27篇 |
1988年 | 31篇 |
1987年 | 17篇 |
1986年 | 10篇 |
1985年 | 13篇 |
1984年 | 13篇 |
1983年 | 9篇 |
1981年 | 8篇 |
1980年 | 8篇 |
1978年 | 13篇 |
1977年 | 10篇 |
1976年 | 8篇 |
1975年 | 8篇 |
1972年 | 8篇 |
1968年 | 10篇 |
1963年 | 7篇 |
排序方式: 共有3750条查询结果,搜索用时 46 毫秒
61.
62.
63.
64.
Chan-Kyung Jane Cho Katherine Sunderland Tom Pickles Francois Bachand Kim N. Chi Scott Tyldesley 《Practical radiation oncology》2019,9(3):e274-e282
PurposeIncreasing the survival of patients with metastatic prostate cancer (PCa) may affect the demand for palliative radiation to bone (PRTB). Our aim was to characterize the use of PRTB in patients who died of PCa in British Columbia between 2003 and 2015.Methods and MaterialsAll patients with a diagnosis of PCa who died during the study period (n = 23,260) were identified from a population-based provincial registry. Patient and treatment characteristics were analyzed. PRTB utilization rate was calculated by year and location. Survival was calculated from the first and the last course of PRTB.ResultsA total of 5701 patients died of PCa, with a median survival from diagnosis of 5.2 years. The overall PRTB utilization rate was 38.6%, with an increasing trend over time. Multiple courses of PRTB were frequent, with 51% of patients receiving ≥2 courses of PRTB. Of the patients who died of PCa (15.2% of the PRTB cohort), 5.4% received PRTB within the last 4 weeks of life, 60% of whom received multiple fractions. Rural areas had a lower referral rate and lower use of PRTB. Patients with longer survival tended to receive multiple courses of treatment. The median survival after the first course of PRTB increased from 8.2 months in 2003 to 2004 to 9.4 months in 2013 to 2014 (P = .04).ConclusionsPRTB is only used in a minority of patients dying of PCa. The majority who die of PCa after PRTB do so within a year of their first course. The use of multifractionation was common in the last 4 weeks of life. Survival after first PRTB increased minimally over time, and additional research is required to identify its association with recent changes in practice. The referral rate and PRTB utilization rate differ between rural and nonrural locations, underlying the importance of accessibility and referral for utilization of PRTB. Investigating other barriers and ensuring equitable access to radiation are needed. 相似文献
65.
66.
67.
Ph. K. E. W. Ballaux K. K. J. Cathenis R. Brondeel F. P. R. Provenief B. A. A. Francois D. J. A. Goossens 《Acta chirurgica Belgica》2013,113(2):99-104
Background : We performed a retrospective analysis of the maze IV procedures performed in our surgical department for concomitant atrial fibrillation.Methods : Preoperative, in-hospital and postoperative follow-up data were collected from 46 consecutive patients who underwent the maze IV operation between April 2006 and December 2010. All electrocardiograms and Holters were reviewed.Results : One patient died in-hospital. During a mean follow-up of 25 ± 16.3 months seven patients died: two related to a hemorrhagic stroke, one due to right ventricular failure, the remainder deaths were not cardiac related. The success rate, defined as no recurrence of AF or atrial flutter with a blanking period of 6 months postoperatively, was 73.7%. Plots of probability of freedom of atrial fibrillation over time are drawn and reach a stable level after one year. Conclusions : The mid term results of the maze IV procedures for concomitant atrial fibrillation are very good. The results are stable for the remainder of follow-up. 相似文献
68.
Francois Moisan Edgar B. Francisco Anamaria Brozovic George E. Duran Yan C. Wang Shalini Chaturvedi Shobha Seetharam Linda A. Snyder Parul Doshi Branimir I. Sikic 《Molecular oncology》2014,8(7):1231-1239
Ovarian cancer is associated with a leukocyte infiltrate and high levels of chemokines such as CCL2. We tested the hypothesis that CCL2 inhibition can enhance chemotherapy with carboplatin and paclitaxel. Elevated CCL2 expression was found in three non‐MDR paclitaxel resistant ovarian cancer lines ES‐2/TP, MES‐OV/TP and OVCAR‐3/TP, compared to parental cells. Mice xenografted with these cells were treated with the anti‐human CCL2 antibody CNTO 888 and the anti‐mouse MCP‐1 antibody C1142, with and without paclitaxel or carboplatin. Our results show an additive effect of CCL2 blockade on the efficacy of paclitaxel and carboplatin. This therapeutic effect was largely due to inhibition of mouse stromal CCL2. We show that inhibition of CCL2 can enhance paclitaxel and carboplatin therapy of ovarian cancer. 相似文献
69.
70.
Nasopharyngeal carcinoma (NPC) is an Epstein-Barr virus-associated head and neck cancer that is most common in eastern Asia. Epstein-Barr virus infection, environmental factors, and genetic susceptibility play important roles in NPC pathogenesis. Jab1/CSN5 is a multifunctional protein that participates in affecting integrin signaling, controlling cell proliferation and apoptosis, and regulating genomic instability and DNA repair. Correlation of Jab1/CSN5 overexpression with poor prognosis for NPC provides evidence that it is involved in the tumorigenic process. In this review, we highlight recent advances in studies of the oncogenic role of Jab1/CSN5 in NPC and its potential as a therapeutic target for this cancer. 相似文献